Immuno-PET and Targeted α-Therapy Using Anti–Glypican-1 Antibody Labeled with (89)Zr or (211)At: A Theranostic Approach for Pancreatic Ductal Adenocarcinoma

Glypican-1 (GPC1) is overexpressed in several solid cancers and is associated with tumor progression, whereas its expression is low in normal tissues. This study aimed to evaluate the potential of an anti-GPC1 monoclonal antibody (GPC1 mAb) labeled with (89)Zr or (211)At as a theranostic target in p...

Descripción completa

Detalles Bibliográficos
Autores principales: Watabe, Tadashi, Kabayama, Kazuya, Naka, Sadahiro, Yamamoto, Ryuku, Kaneda, Kazuko, Serada, Satoshi, Ooe, Kazuhiro, Toyoshima, Atsushi, Wang, Yang, Haba, Hiromitsu, Kurimoto, Kenta, Kobayashi, Takanori, Shimosegawa, Eku, Tomiyama, Noriyuki, Fukase, Koichi, Naka, Tetsuji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Society of Nuclear Medicine 2023
Materias:
Basic Science Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10690121/
https://www.ncbi.nlm.nih.gov/pubmed/37827841
http://dx.doi.org/10.2967/jnumed.123.266313

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10690121/
https://www.ncbi.nlm.nih.gov/pubmed/37827841
http://dx.doi.org/10.2967/jnumed.123.266313

Ejemplares similares